Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Synopsys, Inc. (SNPS) Price & Performance

ADMA Biologics IncTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Synopsys, Inc. — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Synopsys, Inc. trades at $410.7 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 35.4× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.

ADMASNPS
Market Cap
$2.22B$78.68B
Sector
HealthTechnology
52-Week High
$20.38$625.80
52-Week Low
$7.60$372.33
Enterprise Value
$2.29B$87.04B

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS